Ino stock news

Here are some recent news and updates about Ino Therapeutics, a biotechnology company focused on developing innovative treatments for various diseases:

Recent News:

  1. INO-3112: Ino Therapeutics Announces Positive Phase 1 Results for INO-3112 in Patients with Advanced Solid Tumors (February 2023)

Ino Therapeutics announced positive results from a Phase 1 clinical trial of INO-3112, a novel immunotherapy candidate, in patients with advanced solid tumors. The trial demonstrated a favorable safety profile and encouraging signs of anti-tumor activity.

  1. INO-4800: Ino Therapeutics Presents Preclinical Data on INO-4800, a Novel Immunotherapy Candidate for the Treatment of Cancer (January 2023)

Ino Therapeutics presented preclinical data on INO-4800, a novel immunotherapy candidate, at the 2023 ASCO-SITC Clinical Immuno-Oncology Symposium. The data showed that INO-4800 induced robust anti-tumor responses and improved survival in preclinical models of cancer.

  1. INO-3112: Ino Therapeutics Receives FDA Orphan Drug Designation for INO-3112 for the Treatment of Ovarian Cancer (December 2022)

Ino Therapeutics announced that the FDA has granted Orphan Drug Designation to INO-3112 for the treatment of ovarian cancer. This designation provides Ino Therapeutics with seven years of market exclusivity for INO-3112 in the United States.

Upcoming Events:

  1. 2023 ASCO Annual Meeting (June 2023)

Ino Therapeutics is scheduled to present data on its immunotherapy candidates, including INO-3112 and INO-4800, at the 2023 ASCO Annual Meeting.

  1. 2023 SITC Annual Meeting (November 2023)

Ino Therapeutics is expected to present data on its immunotherapy candidates at the 2023 SITC Annual Meeting.

Recent Financials:

  1. Q4 2022 Earnings Release (February 2023)

Ino Therapeutics reported its Q4 2022 earnings, which included a net loss of $14.1 million and a cash balance of $143.1 million as of December 31, 2022.

  1. 2022 Year-End Financial Results (February 2023)

Ino Therapeutics reported its 2022 year-end financial results, which included a net loss of $54.1 million and a cash balance of $143.1 million as of December 31, 2022.

Please note that the information provided is subject to change and may not be up-to-date. It's always a good idea to check the company's website or recent news articles for the most current information.